reviparin


Also found in: Wikipedia.

reviparin

Vascular disease An LMW heparin for ↓ the risk of DVT in Pts requiring prolonged immobilization
References in periodicals archive ?
Lastly, Wirth and coworkers (9) randomized 262 patients undergoing elective knee arthroscopy to receive either no treatment or reviparin once daily subcutaneously for 7 to 10 days.
One clinical trial using reviparin, a low molecular weight heparin, demonstrated superiority to unfractionated heparin in reducing thrombus size for patients with DVT (Breddin, Hach-Wunderle, Nakov, & Kakkar, 2001).
The third RCT evaluated reviparin (another European LMWH) vs placebo in 440 outpatients with lower limb injuries, of whom 293 had fractures.
NEW ORLEANS -- Antithrombotic treatment, in the form of the low-molecular-weight heparin reviparin, has been shown for the first time to safely improve the outcomes of patients with an acute myocardial infarction.
But the value of adding reviparin or a similar agent remains in doubt when patients are treated with the fibrin-specific drugs typically used for thrombolysis in the United States, such as alteplase (tissue plasminogen activator), reteplase, and tenecteplase.
The use of the low-molecular-weight heparins (LMWHs) dalteparin, enoxaparin, nadroparin, reviparin, and tinzaparin resulted in only one vertebral fracture in 486 pregnancies at 21 centers in one study reviewed.
Participants were assigned to one of three treatment regimens: intravenous administration of unfractionated heparin; subcutaneous administration of a low-molecular-weight heparin, reviparin, twice a day for 1 week; or subcutaneous administration of reviparin once a day for 4 weeks.
A recent investigation compared subcutaneous LMW heparin and standard intravenous heparin in symptomatic patients suffering from acute DVT Intravenous standard heparin was administered to one group and reviparin, a LMW heparin, was subcutaneously administered twice daily to another group of DVT patients.
Dalteparin, darbepoetin, dasatinib, dexamethasone + neomycin sulphate + polymyxin B sulfate, epoetin beta, epoetin theta, epoetin zeta, erlotinib, estradiol + cyproterone, etoricoxib, everolimus, follitropin beta, formoterol + beclomethasone, fusidic + betamethasone, fusidic + hydrocortisone , goserelin, hydromorphone hydrochloride, ketorolac, levothyroxine + liothyronine, Linezolid, nadroparin, paliperidone palmitate, pazopanib, pegfilgrastim, piribedil, progesterone, prothipendyl, Reviparin, risperidone, sildenafil, sumatriptan, tinzaparin, tobramycin, tobramycin + dexamethasone, voriconazole.
LMWH preparations evaluated were certoparin, dalteparin, enoxaparin, nadroparin, reviparin, and tinzaparin.